Overview

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Phase:

Phase 2

Details

Lead Sponsor:

Allergan

Treatments:

Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions